In spite of recent treatment targets for cerebral edema and ICP including the Na+-K+-2Cl− co-transporter (NKCC1) and the SUR1-regulated NCCa-ATP (SUR1/TRPM4) channel [44], osmotherapy remains typically administered [36, 44]. The gene discussed is SLC12A2; the disease is brain edema.